Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT00939159 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Low Accrual

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: LBH589

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]